{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:18:14Z","timestamp":1780399094222,"version":"3.54.1"},"reference-count":16,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Active surveillance (AS) is the preferred management approach for patients with low\u2010risk prostate cancer (PC); yet whether younger patients with favorable\u2010intermediate\u2010risk (FIR) PC experience increased mortality\u2010risk when electing AS remains unknown. We evaluated all\u2010cause, PC\u2010specific, and non\u2010PC\u2010specific mortality (ACM, PCSM, and non\u2010PCSM) in younger patients with FIR PC managed with either AS\/watchful\u2010waiting (WW) or immediate definitive treatment, stratified by race.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study using SEER data (2010\u20132020). Patients included were &lt;\u200960 years\u2010old with FIR PC. The primary outcome was ACM, secondary outcomes PCSM and non\u2010PCSM. Multivariable Cox and Fine\u2010Gray competing\u2010risk regressions were used, adjusting for known prognostic factors. Interaction by race (White vs underrepresented minority [URM]) was explored. Statistical significance was set at\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.025 (Bonferroni\u2010adjusted).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 3,832 patients, 127 died (3.31%), including 18 of the 127 deaths from PC (14.17%). Initial treatment with RP\/RT did not significantly reduce ACM or non\u2010PCSM compared to AS\/WW in White (ACM AHR, 0.92; 95% CI, 0.44\u20131.94; non\u2010PCSM AHR, 1.36; 95% CI, 0.53\u20133.46) or URM patients (ACM AHR, 0.68; 95% CI, 0.33\u20131.43; non\u2010PCSM AHR, 1.04; 95% CI, 0.44\u20132.44). However, after adjustment for multiplicity RP\/RT significantly reduced PCSM\u2010risk compared to AS\/WW in URM (AHR, 0.03; 95% CI, 0.00\u20130.48;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), but not in White patients (AHR, 0.21; 95% CI, 0.05\u20130.88;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) although the median follow\u2010up was 6.5\u2010months longer in URM patients undergoing AS\/WW compared to RP\/RT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early mortality\u2010risks were similar and low in patients age &lt;\u200960 years with FIR PC managed with AS\/WW compared to RP\/RT, irrespective of race.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70156","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:13:52Z","timestamp":1773087232000},"page":"839-845","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surveillance Versus Treatment for Favorable Intermediate\u2010Risk Prostate Cancer and Mortality\u2010Risk"],"prefix":"10.1002","volume":"86","author":[{"given":"Mutlay","family":"Sayan","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Brigham and Women's Hospital and Dana Farber Cancer Institute Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetkin","family":"Tuac","sequence":"additional","affiliation":[{"name":"Department of Statistics Ankara University Ankara T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Urology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"},{"name":"Center for Surgery and Public Health Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Dall","sequence":"additional","affiliation":[{"name":"Department of Urology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"},{"name":"Center for Surgery and Public Health Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Urology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"},{"name":"Center for Surgery and Public Health Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-0762","authenticated-orcid":false,"given":"Jonathan E.","family":"Leeman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Brigham and Women's Hospital and Dana Farber Cancer Institute Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Brigham and Women's Hospital and Dana Farber Cancer Institute Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Brigham and Women's Hospital and Dana Farber Cancer Institute Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"D'Amico","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Brigham and Women's Hospital and Dana Farber Cancer Institute Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.12.017"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000002757"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0019"},{"key":"e_1_2_12_7_1","volume-title":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Madrid 2025","author":"Guidelines E.","year":"2025"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00434"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.20580"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.04.003"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.17.1985"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470594001"},{"key":"e_1_2_12_13_1","volume-title":"Nonparametric Statistical Methods","author":"Hollander M.","year":"2013"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/b97377"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_12_17_1","volume-title":"Applied Linear Statistical Models","author":"Kutner M. H.","year":"2005"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.70156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:43:37Z","timestamp":1780397017000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/pros.70156"],"URL":"https:\/\/doi.org\/10.1002\/pros.70156","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}